OpGen to Present Data Showing Acuitas(R) Tests are Effective Tools for Investigating Transmission of "Super Bugs"
OpGen Reports Second Quarter Financial Results and Provides Business Update
OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
OpGen to Acquire AdvanDx, Inc.
OpGen Closes $6 Million Financing With Merck GHI to Expand Infectious Disease Diagnostic Testing Capabilities
Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
OpGen Reports First Quarter Financial Results and Provides Business Update
OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
OpGen Releases Next-Generation Molecular Testing and Bioinformatics Solution for Combating Multi-Drug Resistant Infections
OpGen's Acuitas(R) MDRO Gene Tests and Bioinformatics Data to be Presented at ASM2015